GlassScriptPhysician profile
Helen Anderson
NPI 1619391364
$5,448.33
in general payments reported to CMS, 2019-2025
42 companies · $5,025 in 2025
The $5,025 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.93 · 2024: $410 · 2025: $5,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,448.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $676.04 | 2025 | Vumerity, Tysabri, Skyclarys |
| Jazz Pharmaceuticals INC. | $495.37 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $399.66 | 2025 | |
| Argenx US, INC. | $298.32 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Livanova USA, INC. | $276.09 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Avadel Cns Pharmaceuticals, LLC | $275.51 | 2025 | Lumryz |
| Tg Therapeutics, INC. | $268.72 | 2024-2025 | |
| Axsome Therapeutics, INC. | $254.04 | 2024-2025 | Sunosi, Auvelity |
| Teva Pharmaceuticals USA, INC. | $230.79 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $183.16 | 2024-2025 | Kisunla, Amyvid, Zepbound |
| Acadia Pharmaceuticals INC | $178.63 | 2025 | Nuplazid |
| Ucb, INC. | $178.01 | 2025 | Nayzilam, Briviact |
| Abbvie INC. | $176.67 | 2025 | |
| Emd Serono, INC. | $166.58 | 2025 | Mavenclad |
| Celgene Corporation | $141.54 | 2025 | Zeposia |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.